1Y Annualised Return
▼-6.59%
3Y Annualised Return
▲22.92%
5Y Annualised Return
▲25.62%
10Y Annualised Return
▲6.25%
Sun Pharmaceutical Industries Stock Performance
|
|
|
Sun Pharmaceutical Industries Company background
Sun Pharmaceutical Industries Ltd, established in 1983 by Dilip S. Shanghvi, is headquartered in Gurugram, Haryana. Listed on both the NSE (SUNPHARMA) and BSE (524715), it has grown to become India’s largest pharmaceutical company and a prominent global specialty generics player. The company focuses on developing, manufacturing, and marketing a wide spectrum of branded and generic formulations, active pharmaceutical ingredients (APIs) and over-the-counter (OTC) products for markets worldwide.
Sun Pharmaceutical Business Segments and Revenue Model
Sun Pharma operates across three major segments: branded generics, specialty generics, and APIs. In India, it sells branded generics covering cardiovascular, dermatology, oncology, neuropsychiatry and gastrointestinal therapies. Globally, it markets generic versions of complex medications as well as specialty drugs under its "Taro" and "Sun Pharma Specialty" verticals. APIs are sold both internally and to third-party manufacturers. The company generates revenue through drug sales across markets, licensing agreements and royalties, research collaborations, and contract manufacturing, supported by its geographically diversified portfolio and strong R&D pipeline.
Sun Pharmaceutical Key Milestones
- 1983: Company founded by Dilip S. Shanghvi and launched first psychiatric formulations.
- 1994: Listed on BSE and NSE
- 1996: Acquired an API plant from Knoll Pharmaceuticals; began its global expansion.
- 2003: Acquired Caraco Pharma (USA) to enter North American market.
- 2007: Acquired Taro Pharmaceutical, strengthening dermatology and generics portfolio.
- 2010: Expanded US presence through acquisition of InSite Vision.
- 2014: Acquired Ranbaxy’s Japanese and certain US assets from Daiichi Sankyo.
- 2015: Received US FDA approval for Absorica, entered specialty dermatology.
- 2016: Acquired Allergan’s branded generics business in 18 emerging markets.
- 2018: Inaugurated large R&D and manufacturing facility in Halol, Gujarat.
- 2020: Launched specialty inhalation products; strengthened presence in chronic disease treatments.
- 2022: Filed over 100 regulatory applications globally; expanded biologics R&D cohort.
- 2023: Launched ArchivaRx specialty biosimilars division; entered emerging markets in Africa and LatAm.
Sun Pharmaceutical ESG and Sustainability
- CSR priorities include healthcare access, employee health initiatives, education outreach, and rural community development
- Commitment to achieving carbon neutrality in manufacturing by 2040
- Waste reduction target: reduce water usage and achieve zero liquid discharge across key plants by 2030
- Focus on inclusive workplace: gender balance, skills development and safety protocols
Sun Pharmaceutical Awards and Recognitions
- Recognised as "India Pharma Company of the Year" by Economic Times HealthWorld
- Received CII Environmental Best Practices Award for sustainability
- Named among "World’s Most Ethical Companies" by Ethisphere Institute
- Taro unit honoured with "Dermatology Company of the Year" at Generics Bulletin Awards
Sun Pharmaceutical Industries Financial Highlights
Over the past
Sun Pharmaceutical Industries Fundamental
Market Cap (in crs)
3,91,739.42
Face Value
1
Turnover (in lacs)
50,289.98
Key Metrics
Sun Pharmaceutical Industries Key Financials
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
13851.4 Cr | 12958.84 Cr | 13675.46 Cr | 13291.39 Cr | 12652.75 Cr |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
54543.48 Cr | 49851.04 Cr | 44520.2 Cr | 39576 Cr | 34333.66 Cr | 33473.48 Cr |
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
2302.62 Cr | 2160.64 Cr | 2917.54 Cr | 3030.67 Cr | 2871.25 Cr |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
10980.1 Cr | 9648.44 Cr | 8560.84 Cr | 3405.82 Cr | 2284.68 Cr | 4186.79 Cr |
Sun Pharmaceutical Industries Result Highlights
Result Summary
-
Sun Pharmaceutical Industries Ltd reported a 13.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.
-
Its expenses for the quarter were up by 6.8% QoQ and 5.8% YoY.
-
The net profit decreased 13.8% QoQ and decreased 19.8% YoY.
-
The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 9.5 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Sun Pharmaceutical Industries Technical Analysis
Moving Averages Analysis
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 2238677 Rs | 3113000 Rs |
Week Rs | 1306323 Rs | 1995849 Rs |
Month Rs | 1393176 Rs | 2323054 Rs |
Resistance & Support
Sun Pharmaceutical Industries Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
989.90 | 99,264.98 | 795 | 1220 | 988.80 | 3.24% | 1.18% | 7.93% | -16.93% | 150.35% | 1.11% | 22.26 | 40.57 | 4.68 | |
1,26,429.67 | 1335 | 1702.05 | 1,564.00 | 4.01% | 5.59% | 5.61% | -0.69% | 51.64% | 1.02% | 24.46 | 40.57 | 3.94 | ||
1,63,648.11 | 4615.55 | 7071.5 | 6,132.50 | 2.88% | -8.42% | 5.56% | 33.03% | 64.67% | 0.49% | 70.07 | 40.57 | 10.99 | ||
1,05,382.64 | 1020 | 1421.49 | 1,260.40 | 3.54% | 0.41% | 5.45% | -7.07% | 49.43% | 0.63% | 15.30 | 40.57 | 3.66 | ||
1,23,581.19 | 2886.45 | 3787.9 | 3,623.00 | 1.02% | 3.70% | 20.05% | 9.06% | 133.93% | 0.16% | 62.19 | 40.57 | 16.28 | ||
1,02,043.06 | 2115.1 | 3054.8 | 2,472.60 | 1.43% | -6.78% | 3.66% | 7.45% | 0.00% | 0.00% | 56.33 | 40.57 | 6.96 |
Sun Pharmaceutical Industries Share Price FAQs
What is Share Price of Sun Pharmaceutical Industries ?
Sun Pharmaceutical Industries share price is ₹1632.40 in NSE and ₹1633.20 in BSE as on 18/8/2025.
How has Sun Pharmaceutical Industries shares performed in the past ?
Sun Pharmaceutical Industries share price in the past 1-year return was -6.31. The Sun Pharmaceutical Industries share hit a 1-year low of Rs. 1553.05 and a 1-year high of Rs. 1960.35.
What is the market cap of Sun Pharmaceutical Industries ?
The market cap of Sun Pharmaceutical Industries is Rs. 391739.42 Cr. as of 18/8/2025.
What is the current P/E ratio of Sun Pharmaceutical Industries ?
The PE ratios of Sun Pharmaceutical Industries is 78.63 as of 18/8/2025.
What is the current PB ratio of Sun Pharmaceutical Industries ?
The PB ratios of Sun Pharmaceutical Industries is 16.09 as of 18/8/2025
What is the Mutual Fund shareholding in Sun Pharmaceutical Industries ?
The Mutual Fund Shareholding in Sun Pharmaceutical Industries was 12.63% at the end of 18/8/2025.
How to buy Sun Pharmaceutical Industries shares?
You can easily buy Sun Pharmaceutical Industries shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Sun Pharmaceutical Industries ?
The 52-week high and low of Sun Pharmaceutical Industries share price is ₹1960.35 and ₹1553.05 as of 18/8/2025.
What is the EPS of Sun Pharmaceutical Industries ?
The earnings per share (EPS) of Sun Pharmaceutical Industries stood at 9.5 during Q1 FY 2025-26.
Please be aware that Sun Pharmaceutical Industries stock prices are subject to continuous fluctuations due to various factors.